FDA Expands Indication for Hemlibra to Include Non-Factor VIII Inhibitors

By Nikki Kean

The FDA has expanded the indication for emicizumab-kxwh injection (Hemlibra, Genentech) to include adults and children with hemophilia A without factor VIII (FVIII) inhibitors. Hemlibra was first approved in 2017 for patients with hemophilia A with FVIII inhibitors.